Aquestive’s $74 Million Initial Public Offering

Cooley advised the underwriters on Aquestive Therapeutics’ $73.9 million initial public offering of 4,925,727 shares of common stock, which includes the partial exercise of the underwriters’ option to purchase additional shares.

BMO Capital Markets and RBC Capital Markets acted as the joint book-running managers for the offering. Wedbush PacGrow and JMP Securities acted as co-lead managers for the offering.

Aquestive Therapeutics, which now trades on the Nasdaq Global Market as “AQST,” is a specialty pharmacy company focused on identifying, developing and commercializing differentiated products to address unmet medical needs.

Cooley advised with a team including Daniel I. Goldberg (Picture), Ryan Sansom, Div Gupta, Dayne Brown, Danielle Gershowitz, Lily Colahan and Adam Alperowicz.

Involved fees earner: Daniel Goldberger – Cooley LLP; Ryan Sansom – Cooley LLP; Div Gupta – Cooley LLP; Dayne Brown – Cooley LLP; Danielle Gershowitz – Cooley LLP; Lily Colahan – Cooley LLP; Adam Alperowicz – Cooley LLP;

Law Firms: Cooley LLP;

Clients: RBC Capital Markets; JMP Securities LLC; Wedbush PacGrow; BMO Capital Markets;

Author: Ambrogio Visconti